Sanofi announced that Health Canada has issued a Notice of Compliance for Dupixent® (dupilumab) for the treatment of patients over 12 with eosinophilic oesophagitis (EOE). EoE is a chronic, progressive inflammatory disease that damages the oesophagus. This is the eighth indication for Dupixent® on label in Canada and the first in gastroenterology.
Two weeks ago Sanofi and Regeneron announced that Health Canada issued a Notice of Compliance for Dupixent® as a treatment of patients 6 months to 5 years with moderate-to-severe atopic dermatitis.